Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Inozyme Pharma ( (INZY) ) is now available.
Inozyme Pharma, a company involved in the biopharmaceutical industry, announced significant changes following its acquisition. As of June 30, 2025, the company terminated its 2020 Employee Stock Purchase Plan and on July 1, 2025, requested the delisting of its shares from Nasdaq, effectively ceasing its public trading status. The merger led to a complete overhaul of its board of directors and executive officers, with new appointments including G. Eric Davis as President and Eric Fleekop as Secretary. Additionally, Inozyme’s certificate of incorporation and by-laws were amended and restated in line with the merger agreement.
The most recent analyst rating on (INZY) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Inozyme Pharma stock, see the INZY Stock Forecast page.
Spark’s Take on INZY Stock
According to Spark, TipRanks’ AI Analyst, INZY is a Underperform.
Inozyme Pharma’s stock score reflects its early-stage biotechnology status with significant operational losses, zero revenue, and ongoing cash burn. Technical indicators show short-term momentum but highlight potential overbought conditions. The negative P/E ratio underscores the lack of profitability, and with no earnings data or corporate events provided, the score is primarily driven by weak financial performance.
To see Spark’s full report on INZY stock, click here.
More about Inozyme Pharma
Average Trading Volume: 2,255,035
Technical Sentiment Signal: Buy
Current Market Cap: $257.6M
For detailed information about INZY stock, go to TipRanks’ Stock Analysis page.